This webinar will describe the epidemiology of multi-drug resistant organisms in Latin America prior to the COVID-19 pandemic, and review the ramifications of the pandemic with regards to antibiotic misuse and overuse in Latin America. The presentation will also cover how diagnostics can be used to guide ideal prescribing practices for hospitalized COVID-19 patients.
The target audience for this activity includes pharmacists and physicians.
At the completion of this activity, the participant will be better able to:
- Describe the prevalence of drug resistant bacteria including ESBLs, CREs, and new resistant strains within the Latin American region.
- Identify the therapeutic option most suitable to treat ESBLs and CREs in Latin America.
- Describe the impact of COVID-19 on healthcare associated infections and on rates of antimicrobial resistance in Latin America.
- Apply and uphold core components of ASPs while working on COVID-19 response efforts.
Silvia Figueiredo Costa, MD, PhD
Professor Infectious Diseases
Coordinator of the Infection in Patients of the Hospital das Clinicas of FMUSP
University of São Paulo-Brazil
María Virginia Villegas MD, MSc
Professor Internal Medicine and Infectious Diseases
Executive Director of CIDEIM and Chief of AMR and AMS Committee for API
University del Bosque of Bogotá - Colombia
Doctor Marnie Peterson, PharmD, PhD
Outreach Coordinator, Antimicrobial Stewardship Project
Center for Infectious Disease Research and Policy CIDRAP
University of Minnesota, USA
Release Date: November 24, 2020
Expiration Date: November 24, 2021
ACPE Credit Designation (Pharmacist CE)
This activity is jointly provided by ProCE, LLC and CIDRAP (Center for Infectious Disease Research and Policy). ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-531-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.25 contact hour (0.125 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty and planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Marnie Peterson, PharmD, PhD has no relevant conflicts of interest to report.
Silvia Figueiredo Costa, MD, PhD has no relevant conflicts of interest to report.
María Virginia Villegas, MD, MSc has disclosed that she has received consulting fees and fees for non-CME/CE services from Merck and Pfizer.
Kristine Moore, MD, MPH has no relevant conflicts of interest to report.
Maya Peters, MPH has no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Potential conflicts of interest were resolved with a peer review process provided by Kristine Moore, MD, MPH.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This CE activity is supported by an educational grant from BioMérieux.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.